Analysis Group HEOR Research Presented at ASCO Genitourinary Cancers Symposium

January 29, 2024

Researchers from Analysis Group’s HEOR, Epidemiology & Market Access practice presented six posters at the American Society of Clinical Oncology’s (ASCO’s) annual Genitourinary Cancers Symposium, which was held January 25–27, 2024, in San Francisco, CA.

The firm’s poster presentations included:

  • “Real-world survival of men with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or enzalutamide (ENZ) in an oncology database: ROME Study,”coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, and Associates Jill Korsiak and Alvi Rahman – in collaboration with researchers from the Winship Cancer Institute of Emory University, Janssen Scientific Affairs, and the Carolina Urologic Research Center.
  • “Analysis of real-world survival for patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or abiraterone acetate (ABI) in an oncology database: ROMA Study,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, and Associates Jill Korsiak and Alvi Rahman – in collaboration with researchers from the Winship Cancer Institute of Emory University, Janssen Scientific Affairs, and the Carolina Urologic Research Center.
  • “Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Managers Carmine Rossi and Laura Morrison, and Senior Research Professionals Annalise Hilts and Lilian Diaz – in collaboration with researchers from the Winship Cancer Institute of Emory University, Janssen Scientific Affairs, and the Duke Cancer Institute.
  • “Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ),” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, Associate Jill Korsiak, and Senior Research Professionals Lilian Diaz and Frederic Kinkead – in collaboration with researchers from Chesapeake Urology, Janssen Scientific Affairs, and Delaware Valley Urology.
  • “Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, Associate Jill Korsiak, and Senior Research Professionals Lilian Diaz and Frederic Kinkead – in collaboration with researchers from Delaware Valley Urology, Janssen Scientific Affairs, and Chesapeake Urology.
  • “Real-world economic burden of patients with metastatic castration-sensitive prostate cancer (mCSPC),” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Laura Morrison, and Senior Research Professionals Ana Urosevic and Frederic Kinkead – in collaboration with researchers from the Duke University Cancer Center, Janssen Scientific Affairs, and the Duke Cancer Institute.

Read more about the 2024 ASCO Genitourinary Cancers Symposium